The independent medical news service

Click through to find out what has changed

Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.

Adding a gonadotropin-releasing hormone analog to cyclophosphamide-containing chemotherapy significantly reduces the risk for premature ovarian insufficiency in premenopausal women with breast cancer, Chinese research shows.

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

The pan-nitric oxide signaling inhibitor NG-monomethyl-l-arginine in combination with taxane merits further investigation in the locally advanced or metastatic triple-negative breast cancer setting, say researchers.

A patient-level meta-analysis has demonstrated a significant reduction in the risk for invasive recurrence with the use of an anthracycline alongside taxane-based chemotherapy for the treatment of early-stage breast cancer.

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

Circulating tumor DNA target mutations may represent a promising prognostic biomarker among women receiving first-line ribociclib plus letrozole for hormone receptor-positive, HER2-negative advanced breast cancer, research suggests.

Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for people with HER2-negative metastatic breast cancer and high tumor mutational burden, phase 2 NIMBUS study data show.

Aromatase inhibitors significantly reduce the risk for breast cancer recurrence relative to tamoxifen in premenopausal women treated with ovarian function suppression, suggests a patient-level meta-analysis.

A phase 3 trial has demonstrated a significant progression-free survival benefit with the oral SERD elacestrant relative to standard of care in pretreated patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Multigene sequencing identifies patients with metastatic breast cancer who will benefit from targeted therapy, but its use must be driven by a framework of actionability, show data presented at the 2021 San Antonio Breast Cancer Symposium.

Adjuvant treatment with metformin does not improve the outcomes of patients with HR-positive or negative early breast cancer, suggest trial data presented at the 2021 San Antonio Breast Cancer Symposium.

Early, structured exercise reduces upper limb disability and improves physical quality of life compared with usual care among women at risk for postoperative complications following breast cancer surgery, UK PROSPER study data show.

Physicians should be aware of the likelihood of pathologic etiology in advanced breast cancer patients who have sustained fractures of the vertebrae, say US researchers.

People with Li-Fraumeni syndrome, who carry pathogenic or likely pathogenic germline TP53 variants, are 24 times more likely to develop cancer than people from the general population, research shows.

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

Germline pathogenic variants in five hereditary cancer genes, including BRCA2, are significantly associated with invasive lobular carcinoma risk, US study findings indicate.

A survey of US oncologists and physicians has shown that their perceived barriers toward genetic counseling and testing for breast cancer vary by patients' race.